Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
4-[(4-Methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide; CGP 57148-d8; Genfatinib-d8
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Imatinib-d8 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Imatinib-d8 usage and description
Imatinib D8 is a deuterated form of Imatinib, a small-molecule tyrosine kinase inhibitor that is used in the treatment of various types of cancers, including chronic myeloid leukemia, gastrointestinal stromal tumors, and other malignancies. The deuterated form of Imatinib, Imatinib D8, is used for pharmacokinetic studies in preclinical and clinical settings.
Imatinib D8 has the same chemical structure as Imatinib, with eight of its hydrogen atoms replaced by deuterium atoms, which are stable isotopes of hydrogen. This modification results in a slight increase in the molecular weight of Imatinib D8, which can be detected by mass spectrometry.
The deuterium substitution in Imatinib D8 provides several advantages for drug development and clinical trials. First, it increases the stability of the molecule, which can improve its pharmacokinetic properties, such as bioavailability, half-life, and tissue distribution. Second, it allows for more accurate analysis of drug metabolism and elimination, as deuterium is easier to detect and quantify than hydrogen.
In summary, Imatinib D8 is a valuable tool for studying the pharmacokinetics and pharmacodynamics of Imatinib and other tyrosine kinase inhibitors in preclinical and clinical settings. Its deuterium substitution provides advantages for drug development and clinical trials, and its chemical properties make it a useful tool for drug analysis and quantification.
